Universal Cells (VY-UC)

Matching Any Donor with Any Patient with Single, Simple Step

Vycellix is positioned to be leader in allogeneic medicines by deploying its highly differentiated, universal cell engineering platform (VY-UC), enabling any donor cell to be delivered to any patient without risk of cellular host immune rejection.

The prospect of administering donor-based cells, tissues or organs without the risk of immune rejection or the need for toxic immunosuppressive drugs is the “Holy Grail” of transplantation; VY-UC represents such a breakthrough.

The major immunological hurdle to the transplantation of allogeneic cells/tissues is the expression of MHC molecules also known as human leukocyte antigens (HLA). Cells modified by Vycellix’s VY-UC CD45 engager avoid immune recognition of grafted cells without impacting HLA while conserving donor cell viability, functionality and persistence.

VY-UC Competitive Landscape